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"There are two objects in medical education: to heal the sick and advance the 
science."  
 Charles H. Mayo. 
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Abstract 
Context: Interstitial cystitis/bladder pain syndrome (BPS/IC) is a debilitating 
chronic disease of unknown etiology. Treatment is not well defined and under 
intense investigation.  
Objective: To review existing literature on treatment of BPS/IC and examine 
current evidence on present and future perspective. 
Evidence acquisition: Pub Med data base was researched and publications in 
English language of the last 2 years were retrieved and analyzed. 
 Evidence synthesis: Mainstays of oral therapies are still empirical due to lack of 
knowledge on etiology of this disease. The few oral drugs that showed enough 
efficacy in placebo controlled trials are amitriptiline, pentosanopolisulfate, 
hydroxyzine and cyclosporine A. As for intravesical treatments reasonable 
evidence is available only for dimetylsulphoxide and resection of visible Hunner 
lesions. Reconstructive surgery can also be recommended in selected cases. 
Further studies into the causes and mechanisms of the disease are paramount 
for the development of effective treatments. Foreseeable therapeutic objectives 
will comprehend oral blockade of sensory nerve receptors, immune system 
modulation, peripheral nerve fiber inactivation/desensitization, anti-proliferative 
factor (APF) blockade and pain gene therapy. Identification of BPS/IC 
phenotypical subgroups should help delineate proper individualized treatment 
which will be aimed at the disease and its multiple manifestations rather than at 
focalized complaints. 
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Conclusions: Present treatment of BPS/IC comprises pain control in conjunction 
with control of supposed underlying bladder disease. Based on identified 
possible therapeutic targets several treatment possibilities warrant further 
investigation. Identification of BPS/IC phenotype subgroups should help 
delineate proper individualized treatment along with a comprehensive disease 
approach. 
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Introduction 
Interstitital cystitis (IC), presently known as Bladder Pain Syndrome (BPS) is a 
disease recognized for over a century but still far from completely understood. A 
definition with increasingly wider use is that of the European Society for the 
Study of Interstitial Cystitis (ESSIC) - pelvic pain, accompanied by at least one 
other symptom, such has persistent urge to void or frequency, in the absence of 
an identifiable cause [1]. The disease was initially thought to course with chronic 
inflammation of the bladder wall, leading to the formation of characteristic 
lesions called Hunner’s ulcers, hence the classic name interstitial cystitis. 
Hunner described what he saw as ulcers using rudimentary nineteenth century 
cystoscopes. In fact Hunner’s ulcers are not ulcers but distinct inflammatory 
lesions that rupture across the mucosa and submucosa at cystoscopy if 
hydrodistention is performed. Therefore they are now referred to as Hunner’s 
lesions. These can be observed mainly in the lateral walls in up to 50% of the 
patients. Glomerulations and petequiae (frail urothelium) are more frequently 
observed lesions but none of the above are pathognomonic [1]. 
However, it was observed that many patients that had symptoms of IC did not 
present with intravesical lesions and some of them had no documentable 
inflammation at all [1]. So “classical” interstitial cystitis (with cystoscopic 
alterations) is now considered to be part of a wider disorder presently called 
Bladder Pain Syndrome in which there are two different types: the “classic” form 
which presents with identifiable bladder lesions and/or chronic inflammation 
features, observed at cystoscopy and histologic exam of bladder wall biopsy 
and the “non-classic” form in which the symptoms exist but the macroscopic or 
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even the histologic changes might not [2]. Furthermore BPS is a designation 
more in line with the present view of the disease as a chronic pain syndrome 
and not a disease of and necessarily coursing with inflammation in the bladder. 
Symptoms can be so severe that patients with BPS/IC may have quality of life 
scores lower than those treated for end-stage renal disease with hemodialysis 
[3]. Although BPS can affect both sexes at any age, the majority of patients are 
women. Up to 12% of women experience some symptoms during their lifetime 
[4]. Clinically confirmed BPS has a prevalence ranging from 230 to 500 per 
100000 [5]. Throughout the years of investigation it became clear that 
pathophysiology of BPS/IC is probably multifactorial [6].  General belief today is 
that after an initial as yet unknown insult, bladder epithelium suffers some 
changes related to an impairment of cellular repair mechanisms, probably 
related to increased levels of antiproliferative factor (APF) which delays 
urothelium regeneration [7]. A lack of continuity of the glycosaminoglycan 
(GAG) layer on the outer surface of the urothelium becomes apparent and this 
contributes to leakage of irritating substances through the bladder wall [6]. This 
phenomenon in turn induces inflammatory infiltration with mast cell 
predominance and increased activation – 70% compared to 10% in healthy 
individuals [7]. Type C sensory nerve fibers become activated and in turn lead 
to local neurogenic inflammation, neural sensitization and neuroplasticity both 
peripherally and centrally [8]. The latter phenomena probably relate to bladder 
hyperalgesia and allodynia [6]. The original insult triggering these mechanisms 
and hence etiology of BPS has yet to be identified. Auto-immune mechanisms, 
unidentified infection, central neurogenic mechanisms, defective gag-layer 
constitution, toxic urinary components are some of the forwarded yet unproven 
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candidates [9]. Allergy was the most prevalent auto-immune disorder, but 
rheumatoid arthritis and inflammatory bowel disease were also several times 
more commonly found in BPS patients than in the general population [10]. An 
association between BPS/IC and other chronic diseases such as inflammatory 
bowel disease, systemic lupus erythematous, irritable bowel syndrome, 
fibromyalgia and panic disorders, has been described leading to the suggestion 
that BPS/IC may be but an aspect of a systemic disease [11, 12]. Recently, 
attention has been drawn to the high prevalence of child abuse experiences, in 
patients with BPS/IC, a life event known to be linked with chronic pain 
development [13]. Sisters of IC patients have 17 times greater probability of 
having the disease pointing also to genetic susceptibility [14]. As the 
understanding of the disease evolved, several attempts to establish a diagnostic 
definition were made. The initial definition proposed by National Institutes of 
Diabetes Digestive and Kidney Diseases (NIDDK) for scientific studies turned 
out to be too restrictive, as almost 60% of patients diagnosed by clinicians did 
not fulfill the criteria. This left NIDDK definition unsuitable for clinical application 
as it may identify only a particular subset of what is increasingly known as BPS 
[3,8]. The European Society for the Study of Interstitial Cystitis (ESSIC) not only 
suggested the name BPS but also proposed a definition that allows the 
inclusion of patients that were until now undiagnosed: chronic (>6 months) 
pelvic pain, pressure or discomfort perceived to be related to the urinary bladder 
accompanied by at least one other urinary symptom such as persistent urge to 
void or frequency. Confusable diseases must be excluded [1]. The International 
Consultation on Incontinence (ICI) followed suit and recommended the same 
terminology [4].  
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In view of present diagnostic and physiopathologic uncertainties the quest is on 
for the establishment of disease and disease-activity markers [15]. 
Antiproliferative factor APF (increased), hemoglobin binding endothelial growth 
factor HB-EGF (decreased), EGF (decreased) ,nerve growth factor (NGF - 
increased) and brain derived nerve growth factor (BDNF - increased) have been 
proposed as likely candidates [15, 16, 17]. Recent application of microarray 
technology to BPS patients and animal models has given further thrust to this 
aspect [18]. 
 
Evidence acquisition 
The unrestricted fully exploded Medical Subject Heading (MeSH) “interstitial 
cystitis”, including all related terms was used to fully search PubMed database 
for the US National Library of Medicine of the National Institutes of Health. 
Publications other than in English were excluded. Thorough review of 
publications in the last two years was performed. Literature update thus 
achieved was used to update treatment knowledge acquired in the last two 
years. 
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Evidence synthesis 
Current treatment strategies 
Defining the best management approach to a BPS/IC/ patient has been difficult 
because valid studies are scarce.  The current management of IC/BPS is 
structured so that minimum harming is inflicted to the patient during treatment. 
Both patient and physician must be aware that some improvement during the 
evolution of the disease is already a victory as there is no definite curative 
treatment.  
After the initial diagnostic approach, which includes clinical history, 
physical examination, urine analysis, cystoscopy with hydrodistension and 
biopsy patients are classifiable according to ESSIC criteria  [9]. Conservative 
treatment is the first step of management. For patients that can identify certain 
triggers related to food and beverages dietary modifications should be taken. 
The most common triggers are citrate and drinks that contain caffeine, alcohol 
or which are carbonated. Patients that refer pelvic floor tenderness during the 
physical exam are likely to benefit from physical therapy such as myofascial 
physical therapy that has been proved to improve significantly the patients’ 
global symptoms after 10 sessions [9,6]. During this initial approach pain may 
be controlled with non-prescription analgesics. When conservative treatment 
options fail to control the symptoms specific treatments should be considered.  
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Oral treatments 
Oral treatments have been widely studied but sodium pentosane polysulphate 
(PPS) is the only FDA approved one [8]. PPS’s effect is elicited by replacement 
of the GAG layer as well as the inhibition of mast cell degranulation, thus 
counteracting two supposed physiopathologic mechanisms of the disease [6]. 
For patients that initially responded to oral PPS it was shown that adding a 
small subcutaneous heparin dose is more effective than administering PPS 
alone [8].  
Other oral agents used in BPS, with reasonable evidence, include amitriptyline, 
histamine-receptor antagonists and cyclosporine A. Amitriptyline was confirmed 
to be a useful agent by a controlled randomized study from Germany in 2004. It 
improves the symptoms as it acts as an anticholinergic and sedative by 
decreasing 5-hydroxytriptamine reuptake which also stabilizes mast cells [20, 
2]. However, an RCT by the Interstitial Cystitis Collaborative Research Network 
(ICCRN) demonstrates that only doses above 50 mg/day are effective [21]. 
Hydroxyzine is a H1-receptor antagonist that inhibits mast cells by blocking 
serotonin release in the bladder. It was proven to decrease the severity of the 
symptoms in 40% and in 55% in patients that had personal history of allergies 
[21].  
H2-receptor antagonists have also been used with significant benefit relative to 
palcebo reported for cimetidine in a RCT [22]. 
Cyclosporin A, an immunosuppressive agent that inhibits T-cell activation, and 
cytokine release, when compared to PPS in a randomized controlled study, was 
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proven to be significantly more effective. However, it was also shown to have 
more and more significant adverse effects [23]. 
Various other oral agents have been used albeit with limited success and are 
thus not mentioned in the present work.  
Intravesical treatments: 
Intravesical treatments are the next step in the recommended management 
pathway, since the use of intravesical agents allows exposure to high 
concentrations of a given agent with limited side-effects [21]. Current possible 
intravesical therapies include: intravesical dimethyl sulphoxide (DMSO), PPS, 
neurotoxins, hialuronic acid and chondroitin sulphate. DMSO is the only FDA 
approved drug for intravesical use in BPS.  It inhibits mast cells and has 
analgesic, anti-inflammatory, muscle relaxant and collagen-dissolution effects 
[24]. Subjective and objective improvement was observed in 53 and 93% of 
patients respectively, in a randomized controlled study of DMSO against 
placebo [25].  
PPS is used intra-vesically to achieve higher concentrations in the bladder, 
since a RCT showed significant advantage of simultaneous PPS oral and 
intravesical use over placebo or oral PPS alone [26].  
Sensory type C fibers are responsible for pain transmission in BPS/IC. Thus this 
symptom might be controlled by C fiber desensitization [24]. Several studies 
showed a beneficial effect of resiniferatoxin (RTX) applied intravesically in 
patients with BPS/IC [21]. However Payne et al in a RCT involving 163 patients 
concluded that RTX was not superior to placebo. Since RTX was never 
commercially available and had to be prepared in laboratory for immediate 
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application, many doubts aroused in the scientific community about preparation, 
container used for drug transport and time elapsed between preparation and 
application in the various studies [27]. However in view of the inconclusive 
results the drug is since not recommended for BPS.  
Besides PPS, GAG layer restitution has been attempted with hyaluronic acid 
and chondroitin sulfate. Good evidence however, is scant for either. 
Intravesical sodium chondroitin sulphate efficacy and safety were recently 
evaluated in a multicentric, placebo controlled but underpowered RCT. The 
results show that the treatment is safe. There was no significant difference 
between the two groups regarding the improvement of symptoms. However, 
while only 22.6% of the vehicle control patients reported moderate or marked 
improvement, in the active group the percentage went up to 39,4% [28]. 
A prospective study by Riedl et al, performed in order to verify the long term 
effect of intravesical hyaluronic acid therapy involved 126 patients followed for 6 
years. Overall positive response to treatment was 87%. Fifty percent of patients 
were asymptomatic after the observation period. 41,7% reported initial 
improvement with recurrence during the first year. Only 8,3% were refractory to 
this treatment. However results were for a subset of patients who had a positive 
modified potassium test [29]. 
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Interventional therapies: 
Hydrodistension (HD) not only allows the visualization of Hunner’s lesion but is 
generally considered to have therapeutic effect by itself. In fact HD increases 
HB-EGF and decreases APF, two important disease and disease-activity 
potential bio-marker molecules in BPS [7]. However clinical evidence for its use 
beyond initial BPS evaluation procedures is scant at the most [30]. 
Neuromodulation 
Long-term results were investigated by Gajewski et al. 72% of the patients 
(n=78) referred improvement after a median follow-up of 61.5 months. However, 
high rates of revision were observed and in 28% of the patients explantation 
was necessary. Neuromodulation should therefore be considered for persistent 
cases and before advancing to more invasive interventions such as surgery [31, 
32]. 
Transurethral resection of Hunner’s lesion induces a good response in 90% of 
the patients. Aiming at lesser morbidity transurethral lesion destruction has also 
been obtained both by fulguration and by laser application with success. 
Transurethral intervention has good results and patients remain symptom-free 
for up to two years. The obvious setback of this invasive treatment is that it is 
only effective in a subset of BPS patients [33, 34]. 
Major surgery is viewed as a last resort. Different types of surgery are available: 
urinary diversion with bladder conservation, supratrigonal cystectomy, 
subtrigonal cystectomy or radical cystectomy including excision of the urethra. 
Supratrigonal cystectomy with enterocystoplasty is the most attractive option. 
Careful patient selection is of major importance and available evidence 
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identifies end stage classic ulcerative disease with bladder contraction as the 
ideal indication for surgery [35]. 
Since such a large portion of patients will be or are become refractory to 
treatment or will respond only partially to it, the practicing clinician dealing with 
BPS must work join in close contact with pain specialist units. The disease will 
be approached even more as a chronic pain picture per se, rather than a 
supposed organ disease and will follow habitual protocol. Any previous 
treatment presenting with some effect will be maintained. 
Future trends in the treatment of BPS 
The previously described approach to BPS treatment is a step by step method 
where often every patient is submitted to the same kind of treatment without 
considering the different kinds of symptoms or associated diseases of each 
patient. However no one treatment is effective in all patients and up to now, no 
means are devised to understand who will respond to which treatment. 
Patel et al suggested a treatment algorithm in which the management was 
based on the patient phenotype dividing the patient’s symptoms into six 
categories: urinary, psychological, organ specific, infection, neurologic and 
tenderness (UPOINT). Treatment in patients with urinary symptoms (frequency, 
urgency outlet problems, incontinence) should include urinary analgesics, 
anticholinergics, alfa-blockers, botulinum injection and neuromodulation. Those 
with psychological diseases that need to be treated with antidepressants should 
receive serotonin- norepinephrine reuptake inhibitors. Organ-specific treatment 
includes DMSO, PPS, bladder instillations, urinary analgesics and herbal 
agents. Infection should be treated with culture-specific antibiotics. Patients with 
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other diseases such as fibromyalgia, irritable bowel syndrome benefit from 
physical and alternative therapies and neuromodulation. When tenderness is 
identified physical therapy, massage, local anesthetics and muscles relaxants 
are appropriate [6]. 
Another way to approach BPS treatment/research might be to take into 
consideration specific subsets of patients according to ESSIC criteria and try to 
link them to responder subsets as exemplified by Riedl et al with modified 
potassium testing [4]. Further management approaches can include treatments 
such as intravesical botulinum toxin and other treatments still in an experimental 
context and dependent on clarification of etiology of BPS. 
BPS treatment – future perspectives 
Antibiotics? 
Bacterial etiology hence antibiotic treatment is periodically reappraised. 
Presence of nanobacteria (NB) was investigated in twenty-seven BPS patients. 
NB were present in eleven of these patients. For these tetracycline treatment 
was performed; both oral and intravesical treatments were given for 3 months. 
After this period NB levels decreased and 36.35% of the patients considered 
themselves cured, 54,55% referred subjective improvement and only one 
patient did not refer any improvement [36]. 
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New pharmacologic targets 
Rudick et al used a murine model of BPS, obtained by pseudorabies virus 
infection, in order to identify potential therapeutic. Type 2 histamine receptor 
and neurokin type I receptor blockade elicited best reduction in pain parameters 
in this model [37]. 
Tanezumab, a humanized monoclonal antibody that specifically inhibits nerve 
growth factor  was investigated in a proof of concept RCT. After 1 single IV 
injection patients evaluated at 6 weeks showed significant better results with 
tanezumab compared to placebo. Doses, treatment regimes are yet to be 
delineated [38]. APF antagonists were shown experimentally to revert tight 
junction damage in laboratory models presenting also a therapeutic possibility 
[39]. Sanchez Freire have forwarded evidence implying that epigenetic 
alterations and their reversal may be key in understanding and treating BPS. In 
fact the authorsshowed that MicroRNAs may medite down-regulation of NK-1 
receptor in BPS. Thus Micro-RNA manipulation might present also a therapeutic 
option in the future [40]. 
Gene therapy 
Opioids are known to diminish pain and hyperactivity, however, these drugs 
induce dependence, bowel and cognitive side effects that are prohibitive to their 
long term use. Gene therapy presents a valid option since it delivers anti-
nociceptive factors directly to bladder afferents. Both viral and non-viral vectors 
have been studied. Non-viral vectors are significantly less immunogenic but 
they do not have an efficient gene delivery as the viral vectors. Yokoyama et al 
studied the effect of targeted and localized expression of enkephalin in afferent 
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nerves that innervate the bladder by gene transfer using replication-defective 
herpes simplex virus (HSV) vectors expressing preproenkephalin, in a rat model 
of bladder hyperactivity and pain. This study showed that the therapy reduced 
the bladder irritation induced by capsaicin and the nociceptive freezing behavior 
was reduced when capsaicin was applied to un-anesthetized mice [41]. Human 
studies are underway with technology in human cancer patients [42]. 
Acupuncture is a well-known technique widely used for chronic pain diseases 
e.g rheumatoid arthritis. In a double-blind, randomized clinical trial comparing 
acupuncture with sham acupuncture therapy in 90 asian patients, 20 treatment 
sessions of acupuncture were twice as effective as sham acupuncture at easing 
symptoms of chronic prostatitis/chronic pelvic pain syndrome. After 10 weeks, 
the acupuncture group improved 4.5 points more on average in NIH-CPSI total 
score than the sham group. No demographic or clinical characteristic was 
associated with response [43]. 
Intravesical therapies 
Hydrodistension under local anesthesia was undertaken with 71% patients 
showing success at one month follow-up and remaining well for medium 20 
weeks. If confirmed this approach would avert the economic and personal 
burden of multiple operating room procedures [44]. 
The alkalinized form of lidocaine  (able to penetrate urothelial barrier) was used 
by Nickel et al intravesically in a RCT. Alkalinized lidocaine had an immediate 
effect on symptoms: mean pain scores measured with a visual analogue scale 
decreased significantly from 6 to 1,8 after the first instillation. Despite being 
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significantly positive, these results again were limited to a subset of patients 
thus justifying phenotyping efforts [45]. 
In order to better understand the responsiveness to intravesical DMSO,  Kim et 
al developed a new transgenic cystitis model that resembles BPS 
histopathology. Both chronic and acute phases of inflammation were studied. 
Results confirmed DMSO is capable of reducing both acute and chronic multiple 
inflammatory manifestations. DMSO or DMSO-derived improved compounds 
might thus have an enhanced role in BPS treatment [46]. 
Intravesical botulinum toxin A injection  
Intravesical botulinum toxin A (Onabotulinum A) injection has been studied as a 
possible treatment as it may have an anti-nociceptive effect on bladder afferent 
pathways and diminishes muscle contractility. Although the results of several 
studies suggest a beneficial effect there is no irrefutable evidence of its role as 
an effective treatment yet. Placebo-controlled studies are needed. The 
injections have been associated with some adverse effects such as urinary 
retention and to decrease this event small doses of toxin should be used and it 
should be injected into the submucosa or at the bladder trigone [47]. 
In a RCT study the difference between hydrodistension and hydrodistension 
plus intravesical botulinum toxin A was analyzed. Of the 67 patients, 44 were 
divided in two groups that received the injections (one group received 200 U 
and the other 100 U) and cystoscopic hydrodistension was performed after two 
weeks. The remaining 23 patients received hydrodistension only. There was 
symptomatic improvement in all groups. However, in the hydrodistension group, 
70% had returned to their previous symptoms after the first month whereas in 
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the OnabotA- treated groups there was improvement of VAS, FBC and 
cystometric bladder capacity at 3 months. At 12 and 24 months the results in 
the active group were 55 and 30% versus 26 and 17% in the hydrodistension 
group [48]. 
Trigonal only injection seemed effective and long lasting since 87% of patients 
(n=23) reported improvement after a 3 month follow-up period in a study by 
Pinto et al. Over 50% referred continuity of the beneficial effect nine months 
after the first treatment. When retreatment was needed similar results were 
obtained. The authors concluded that this treatment is safe, effective and can 
be repeated [17]. 
Laboratory engineered Onabotulinum toxin A, allowing for a more selective 
binding of the toxin to sensory fibers, will represent a major advance in this field. 
Basic work to this end is underway. 
Conclusions: 
Present treatment of BPS comprises multistep pain control in conjunction with 
control of any underlying bladder disease. Available treatments are largely 
insufficient. However, results are probably undermined by the lack of common 
terminology among researchers and especially by lack of clear disease subtype 
identification. Even so e.g. amitriptyline, PPS, hydroxyzine, DMSO, cimetidine, 
cyclosporine A, transurethral ressection and surgery have been proven 
effective. Several treatment hypothesis warrant further investigation, based on 
identified therapeutic targets. Such is the case for alkalinized lidocaine, 
neurokinin, histamine and nerve growth receptor blockers, intravesical 
botulinum toxin type A and preproenkephalin viral vector carriers. Identification 
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of BPS phenotype subgroups, be it through clinical or physiopathological 
criteria, should help delineate proper individualized treatment along with a more 
comprehensive disease approach. 
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Take home message 
BPS is in urgent need of uniformed phenotyping in order to maximize effect of 
presently known therapies and results of new therapeutic target research.  
Exciting new armamentarium (neurotoxins, channel blockers, gene therapy) will 
benefit patients with a clear aiming. 
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